Why the study?
Do cardiovascular and inflammatory biomarkers measured on admission predict short- and long-term all-cause mortality in patients with community-acquired pneumonia?
Do cardiovascular and inflammatory biomarkers measured on admission predict short- and long-term all-cause mortality in patients with community-acquired pneumonia?
MR-proADM is a strong, independent predictor of short- and long-term mortality in community-acquired pneumonia, outperforming standard inflammatory markers and clinical scores.
No takes yet. Share an insight, caveat, or question.
MR-proADM may enhance CAP mortality prediction; extends biomarker comparisons but requires prospective validation before clinical adoption.
Krüger et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: